The UK and US have hammered out a important bilateral deal that will maintain no import taxes on British medicine exports being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the NHS. This pledge guarantees that tariffs on these key products will stay at nothing for a timeframe of three years.
This development follows earlier statements to hike tariffs on patented pharmaceutical products, with figures floated up to 100%.
"This agreement between the Britain strengthens the international landscape for cutting-edge drugs and brings much-needed fairness to transatlantic medicine commerce," an announcement noted.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's biggest goods shipped to the America, which is by far the largest buyer for leading UK drugmakers.
Statistics indicate that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This deal safeguards jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Key British Pledges
The pact entails several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The deal comes amid a long-running row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were exacerbated by claims that American customers were charged several times more for the same drugs than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
